Taiwan Bio Therapeutics Co (ROCO:6892) ROCE % : -18.87% (As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Taiwan Bio Therapeutics Co ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Taiwan Bio Therapeutics Co's annualized ROCE % for the quarter that ended in Dec. 2023 was -18.87%.

Taiwan Bio Therapeutics Co ROCE % Historical Data

The historical data trend for Taiwan Bio Therapeutics Co's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Taiwan Bio Therapeutics Co ROCE % Chart

Taiwan Bio Therapeutics Co Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

-73.67

-65.12

-28.17

-26.80

-25.05

Taiwan Bio Therapeutics Co Semi-Annual Data
	Dec19	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
ROCE %	Get a 7-Day Free Trial			-17.41	-24.57	-22.04	-27.68	-18.87

Taiwan Bio Therapeutics Co ROCE % Calculation

Taiwan Bio Therapeutics Co's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-212.204	/	( ( (871.01 - 56.616)	+	(941.761 - 61.617) )	/ 2 )
	=	-212.204	/	( (814.394	+	880.144)	/ 2 )
	=	-212.204	/	847.269
	=	-25.05 %

Taiwan Bio Therapeutics Co's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	-175.752	/	( ( (1049.666 - 67.505)	+	(941.761 - 61.617) )	/ 2 )
	=	-175.752	/	( ( 982.161	+	880.144 )	/ 2 )
	=	-175.752	/	931.1525
	=	-18.87 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

Taiwan Bio Therapeutics Co (ROCO:6892) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Taiwan Bio Therapeutics Co ROCE % Related Terms

Thank you for viewing the detailed overview of Taiwan Bio Therapeutics Co's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Taiwan Bio Therapeutics Co (ROCO:6892) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Taiwan Bio Therapeutics Co Ltd (ROCO:6892) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 18, Lane 120, Hu Road, Section 1, 6th Floor, Neihu District, Taipei, TWN

Website

http://www.twbio-thera.com

Taiwan Bio Therapeutics Co Ltd is a regenerative medicine company specializing in the development of new cell medicines. It provides cell product process development and foundry (CDMO/CMO) services.

Taiwan Bio Therapeutics Co (ROCO:6892) Headlines

No Headlines